Skip to main content

Table 4 Disease-specific survival among patients with colorectal cancer according to CIMP status

From: Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review

CIMP definition

First author (year)

Subgroup

Subgroup size

Analysis

Survival

HR (95 % CI)

Comparison group

p value

Covariates adjusted for

CIMP+/CIMP-H

CIMP-L

CRC patients

         

 D 2

Simons (2013) [31]

All

27

M

DSS

3.67 (1.70–7.91)a

 

CIMP−

 

Age, sex, stage, locationb

 D 2

Samadder (2013) [30]

All

563

M

DSS

1.06 (0.65–1.35)

1.19 (0.72–1.97)

CIMP-N

0.74

Age, stage, grade, locationc

 D 4

Dahlin (2010) [8]

All (NSHDS)

190

M

DSS

1.84 (0.87–3.89)

2.01 (1.20–3.37)

CIMP-N

 

Age, sex, stage, locationd

 D 4

Dahlin (2010) [8]

All (CRUMS)

414

M

DSS

1.10 (0.59–2.03)

1.48 (1.00–2.22)

CIMP-N

 

Age, sex, stage, locationd

 D 4

Dahlin (2011) [24]

All

484

M

DSS

1.09 (0.59–2.03)

1.47 (0.98–2.20)

CIMP-N

 

Age, sex, stage, locationd

CRC patients by microsatellite instability

        

 D 1

Samowitz (2005) [13]

MSS, colon

803

M

DSS

0.97 (0.70–1.36)

 

CIMP−

 

Age, stage, location, BRAF

 D 4

Dahlin (2010) [8]

MSS (NSHDS)

166

M

DSS

3.05 (1.40–6.63)

1.89 (1.12–3.21)

CIMP-N

 

Age, sex, stage, locationd

 D 4

Dahlin (2010) [8]

MSS (CRUMS)

338

M

DSS

1.38 (0.62–3.07)

1.45 (0.95–2.23)

CIMP-N

 

Age, sex, stage, locationd

 D 4

Dahlin (2010) [8]

MSI (CRUMS)

62

M

DSS

1.23 (0.13–11.23)

3.87 (0.46–32.39)

CIMP-N

 

Age, sex, stage, locationd

CRC patients by location of CRC

         

 D 4

Ogino (2009) [19]

Colon

649

M

DSS

0.44 (0.22–0.88)

0.78 (0.54–1.11)

CIMP-N

 

Age, stage, BRAF, KRAS, MSIe

 D 1

Samowitz (2005) [13]

MSS, colon

803

M

DSS

0.97 (0.70–1.36)

 

CIMP−

 

Age, stage, location, BRAF

  1. CI confidence interval, CRUMS and NSHDS are the names of two studies included in Dahlin et al. study, DSS disease-specific survival, HR hazard ratio, M multivariate analysis, U univariate analysis
  2. aData come from early follow-up (≤2 year). Data of late follow-up (>2 year) was 1.41 (0.43–4.57)
  3. bOther covariates included in the multivariate analysis are differentiation grade and initial adjuvant therapy
  4. cOther covariates included in the multivariate analysis are chemotherapy and radiation therapy
  5. dOther covariate included in the multivariate analysis is adjuvant chemotherapy
  6. eOther covariates included in the multivariate analysis are year of diagnosis, sex, site, and tumor grade